IMMUNOCLIN CORP (IMCL)

0.16
OTC Markets
Prev Close 0.16
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.19
Exchange OTC Markets
Shares Outstanding 28.83B
Market Cap 4.58M
Div & Yield N.A. (N.A)
Monday's Health Winners & Losers

Monday's Health Winners & Losers

Accentia climbs on SinuNase study results.

ImClone Settles Patent Dispute for $65 Million

The biotech will pay Repligen and MIT in a lump sum.

Fast Money Recap: Best Volatility Bets

Fast Money Recap: Best Volatility Bets

With the market bouncing, the crew offers their best stock picks and the safest haven.

Tuesday's Daily Blog Watch

Tuesday's Daily Blog Watch

Nordstrom is fashionable here, and hunting for dividends.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Health care stocks are flat, despite a solid gain by Bradley and a fall by Cortex.

Monday's Daily Blog Watch

Monday's Daily Blog Watch

An iPod insider trading scandal, and should you take a bite of Apple here?

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Amgen and ImClone climb on analyst upgrades.

ImClone Names John Johnson CEO

The former J&J executive joins a long line of ImClone chiefs.

Wednesday's Daily Blog Watch

Wednesday's Daily Blog Watch

Top growth plays, and the long case for UTX.

ImClone's Profits Decline

But the biotech company beats analysts' EPS estimates by 6 cents.

Bristol-Myers, ImClone Expand Erbitux R&D

The companies will invest as much as 'several hundred million dollars' to conduct more research of the tumor drug.

Amgen Beats, Despite Weak Sales

The pharmaceutical giant posted slow growth in the second quarter.

These 10 Biotechs Have Drugs Near Finish Line

These 10 Biotechs Have Drugs Near Finish Line

Here's a list of stocks set to report phase III trial results.

Icahn Lost Lear, but Bigwigs Lost Even More

Icahn Lost Lear, but Bigwigs Lost Even More

The buyout failure highlights top executives' poor choices.

Fat May Weigh Down Glaxo's Tykerb Sales

Fat May Weigh Down Glaxo's Tykerb Sales

Research suggests a lower dosage of the cancer drug works better with a high-fat meal.

Flying High Again

Stocks soar into record territory amid more M&A and strong same-store sales. Helene Meisler and James "Rev Shark" De Porre provide insights.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

ImClone slumps on disappointing data.

Study Sinks ImClone Shares

The stock drops 8% after Erbitux fails in a lung cancer study.

Why Now's the Time to Buy Biotech

Why Now's the Time to Buy Biotech

Using China as a comparison, it's clear biotech is undervalued currently.

Stock Upgrades, Downgrades from TheStreet.com Ratings

Stock Upgrades, Downgrades from TheStreet.com Ratings

Brocade, ImClone and Penske downgraded; NRG and Advance America upgraded.

Tuesday's Health Winners & Losers

ImClone is falling.

Tuesday's Daily Blog Watch

Tuesday's Daily Blog Watch

Taking a look at LoopNet, and the latest battle in search.

The Top Stocks From Biotech Confab ASCO

The Top Stocks From Biotech Confab ASCO

The quick takeaway: Onyx stands out from the field.

ImClone Study Signals Hurdle for Erbitux

ImClone Study Signals Hurdle for Erbitux

Results don't suggest a significant market-share assault on Genentech's Avastin.

The Hot Stocks at Biotech Confab ASCO

The Hot Stocks at Biotech Confab ASCO

Here's a helpful guide to the key data being released.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

This week, ASCO's clinical-data leaks, and why they blacklisted Adam.

What a Week: Bears Bloodied

What a Week: Bears Bloodied

Buyouts power the Dow and S&P to another round of new highs.

Biotech Confab ASCO Laments Insider Leaks

Biotech Confab ASCO Laments Insider Leaks

ASCO officials are dismayed confidential data are finding their way into traders' hands.

ASCO Data Springs More Biotech Leaks

ASCO Data Springs More Biotech Leaks

Volatility in stocks shows some investors already trading on 'confidential' research.

Biotech Bonanza: Stocks to Watch at ASCO

Biotech Bonanza: Stocks to Watch at ASCO

Here's what to look for at biotech's June 1 confab.